Mindfulness-based interventions (MBIs) are increasingly being applied in healthcare settings around the world, in particular as a means of managing stress in those with chronic conditions. Various meta-analyses examining their use in this area have been conducted over the past decade, all of which suggest some benefit, but in general there is a notable call for more rigorous research, to include both active control groups, and a wider demographic spread. 1, 2, 3 The highestquality evidence for MBIs is for the use of mindfulness-based cognitive therapy (MBCT) in the treatment of those with recurrent depression, and this is reflected in national clinical guidelines for the condition. 4 The use of MBIs in the multiple sclerosis (MS) population has not been widely studied. A recent systematic review demonstrated a relative paucity of high-quality research, with evidence for effectiveness being limited to improvements in measures for anxiety, depression, health-related quality of life, standing balance, and fatigue. 5 The UK National Institute for Clinical Excellence (NICE) now includes the recommendation of MBIs as one potential treatment for fatigue. 6 A major issue concerning the use of MBIs in healthcare settings is that, despite various models, there is no consensus definition on the construct of mindfulness itself, and further, no one is really sure how they work. MBIs originally derive from a combination of Buddhist meditation practices and Hatha Yoga postures, both of which are believed to have quite distinct neural mechanisms, although there is a degree of overlap, with attention regulation systems playing a prominent role. 7 Professor Jon Kabat-Zinn, who introduced their use in clinical settings in the 1980s, has defined mindfulness as: 'paying attention in a particular way: on purpose, in the present moment, and nonjudgementally'. 8 Typically, MBIs are delivered in a standard group format, with core content focusing on the development of 'mindfulness' through breath awareness, body awareness, and mindful movement. 8
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In their randomised controlled trial, Bogosian et al. 10 can be seen to extend the boundaries defined above. The authors report on a novel and innovative approach to delivering an MBI specifically for people with progressive MS. Using a virtual classroom approach, they have developed a SKYPE distant-delivered MBI, tailored to meet the needs of this particular population. The intervention is informed by the MBCT approach to treating depression, with the depression-specific cognitive content having been modified to address more generic issues associated with progressive MS. A range of key stakeholder opinions informed development of the intervention, which resulted in the authors employing an MBI that did not include mindful movement in any format, which is a significant departure from more traditional approaches. A range of relevant measures were collected (general distress, anxiety, depression, pain, impact of MS, quality adjusted life years) in an attempt to ascertain the potential effectiveness and cost-effectiveness for an MBI in this group.
The key findings from the Bogosian et al. 10 study are:
• • This type of approach seems feasible for people with progressive MS and more marked physical disability. • • Significant improvements in distress scores, with large and sustained effect sizes. • • Significant improvements in scores for anxiety, depression, and psychological impact of MS, with medium and sustained effect sizes. • • Non-significant improvements in fatigue, pain, and physical impact of MS. • • A high likelihood of cost-effectiveness.
There are some interesting points to consider here. Firstly, because this study used an online classroom, the researchers were able to recruit nationally -this has notable implications for resource allocation in a financially constrained, nationalised health service, such as that in the UK. It is impossible to say how the virtual classroom compares to the more standard experience and dynamics of being in a group, taking place in the same physical space. Secondly, as noted, the intervention did not include mindful movement. It is not possible to determine how this may have impacted on findings in a small pilot study such as this, but it does reinforce the validity of questioning what the active ingredients in an MBI actually involve, and whether they are the same for every level of function or disability. Indeed, physical activity is widely seen as a key component in MS neuro-rehabilitation 6, 11 and can be delivered in myriad different ways. In this regard, it is also interesting to note that the main participant benefits in the study were in the mental health domain.
Bogosian et al. 10 have added substantially to the empirical literature on the use of MBIs in people with MS and it is important that these preliminary findings are followed up in a definitive trial, ideally with an active control comparison group -a common criticism of the mindfulness literature in general. Important as these findings are, we need to hear more from those that matter most in this story -people with MS. Qualitative research, which can be nested within trials, could help answer such questions as: how do people with MS find mindfulness, what works for them, and why, as well as what aspects, if any, are unhelpful? Collating such information together with future research aimed at determining the active components of MBIs can be used to inform clinicians and patients alike as to whether an MBI might be a suitable treatment for them, or not.
